Network meta-analysis of oral administration of Chinese patent medicines with calcium dobesilate in the treatment of nonproliferative diabetes retinopathy
Objective To comprehensively analyze the efficacy and safety of oral administration of Chinese patent medicines with calcium dobesilate(CD)in the treatment of nonproliferative diabetes retinopathy(NPDR).Methods Randomized controlled trials of oral administration of Chinese patent medicines with calcium dobesilate in the treatment of NPDR in the Chinese and foreign databases(CNKI,Wanfang,VIP,Sinomed,PubMed,Cochrane Library,Embase)from the establishment of the database to March 26,2023 were retrieved.Quality evaluation was conducted using the Cochrane Risk of Bias(ROB)1.0 tool,and data was statistically analyzed using ADDIS 1.16.8 and Stata15.0 software,and relevant graphs were drawn.Results The results of the network meta-analysis showed that the overall clinical effective rate of efficacy ranked as follows:compound Danshen dripping pills combined with CD＞Qiming granules combined with CD＞compound Xueshuantong capsules combined with CD＞Shuangdan Mingmu capsules combined with CD＞CD alone.The adverse reactions of Chinese patent medicines combined with CD were less than those of CD alone.Conclusion The clinical efficacy of oral administration of Chinese patent medicines combined with CD in the treatment of NPDR is better than that of CD alone,and the safety is better.However,it is limited by the quality and quantity of research,and we hope to get more high-quality research evidence in the future.
Chinese patent medicinesCalcium dobesilateNonproliferative diabetes retinopathyNetwork meta-analysis
万方数据
维普
